laitimes

The UK Medicines and Medical Products Regulatory Agency has approved the GlaxoSmithKline antibody drug Sotrovaimab for COVID-19 treatment

Financial Associated Press, December 2, GlaxoSmithKline said that preclinical data show that the company's new crown drug Sotrovaimab is active against Omilon. The UK Medicines and Medical Products Regulatory Agency has approved the GlaxoSmithKline antibody drug Sotrovaimab for COVID-19 treatment.

Read on